Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept
加拿大皇家銀行將Avalo Therapeutics的評級從跑贏大盤下調至板塊表現，目標股價從9美元下調至0.75美元，投機風險保持不變
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊